Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
InVivo Therapeutics said today it won Health Canada approval to initiate a clinical study of its neuro-spinal scaffold in patients with acute, complete AIS A cervical spinal cord injuries.
The Cambridge, Mass.-based company said it is in late stage conversations with several site research ethics boards, and expects to announce the 1st Canadian site for the study “in the coming weeks.” Read more
Johnson & Johnson subsidiary Ethicon said today it closed its acquisition of Torax Medical, and its Linx acid reflux treatment portfolio, for an undisclosed amount.
The Linx system from Shoreview, Minn.-based Torax is an implant composed of interlinked titanium beads with magnetic cores that augments the esophageal sphincter’s barrier function to prevent reflux in patients with gastro-esophageal reflux disease. Torax is also developing a similar device, Fenix, designed to treat fecal incontinence. Read more
Retractable Technologies said on Monday that the US Supreme Court denied its request to review an overturned $352 million anti-trust win over Becton Dickinson.
With the ruling, the case goes back to the Eastern District of Texas, where it was sent by the Fifth Circuit Court of Appeals, for a redetermination of the amount of damages to which BD must disgorge. Read more
TransEnterix said today it is looking to expand the use of its Senhance robotic surgical system to include hernia repair surgeries, touting that the system has been used in for the 1st time in such procedures in Germany.
Research Triangle Park, N.C.-based Transenterix said that Dr. Dietmar Stephan and Dr. Frank Willeke performed up to 3 hernia surgeries with the robotic platform per day during the system’s 1st weeks of clinical use at the St. Marien-Krankenhaus Siegen hernia repair center in Germany. Read more
Valeritas today priced its upcoming initial public offering, looking to raise $52.5 million through the sale of 5.25 million shares at $10 per share.
The offering includes a 30-day underwriters option for the purchase of an additional 787,500 shares, which would take the total funding possible in the round to approximately $60 million. Read more